Autoimmune autonomic ganglionopathy

Background: Autoimmune autonomic ganglionopathy (AAG) is an acquired immune-mediated form of diffuse autonomic failure. Many patients have serum antibodies that bind to the ganglionic acetylcholine receptors (AChRs) that mediate fast synaptic transmission in autonomic ganglia. Previous clinical studies and observations in animal models suggest that AAG is an antibody-mediated neurologic disorder. Methods: Using whole-cell patch clamp techniques, we recorded ganglionic AChR currents in cultured human IMR-32 cells and examined the effects of bath application of IgG derived from patients with AAG. Results: IgG from seven patients with AAG all produced a progressive decline in whole-cell ganglionic AChR current, whereas IgG from control subjects had no effect. The effect was abolished at low temperature. Fab antibody fragments had no effect unless a secondary antibody was added concurrently. IgG from one patient also produced a more immediate reduction of ganglionic AChR current. Conclusions: The characteristics of antibody-mediated inhibition of ganglionic acetylcholine receptor (AChR) current are consistent with modulation and blocking of the membrane AChR, analogous to the effects of muscle AChR antibodies in myasthenia gravis. Our observations demonstrate that antibodies in patients with autoimmune autonomic ganglionopathy (AAG) cause physiologic changes in ganglionic AChR function and confirm that AAG is an antibody-mediated disorder.

[1]  P. Sandroni,et al.  Efficacy of immunotherapy in seropositive and seronegative putative autoimmune autonomic ganglionopathy , 2009, Neurology.

[2]  D. Lachance,et al.  Ganglionic acetylcholine receptor autoantibody: oncological, neurological, and serological accompaniments. , 2009, Archives of neurology.

[3]  D. Goldstein,et al.  Autoimmune autonomic ganglionopathy: treatment by plasma exchanges and rituximab , 2009, Clinical Autonomic Research.

[4]  D. Goldstein,et al.  Clinical laboratory evaluation of autoimmune autonomic ganglionopathy: Preliminary observations , 2009, Autonomic Neuroscience.

[5]  P. Sandroni,et al.  Other autonomic neuropathies associated with ganglionic antibody , 2009, Autonomic Neuroscience.

[6]  T. Mimori,et al.  Autoimmune autonomic ganglionopathy with Sjögren's syndrome: Significance of ganglionic acetylcholine receptor antibody and therapeutic approach , 2009, Autonomic Neuroscience.

[7]  S. Vernino,et al.  Autonomic ganglia, acetylcholine receptor antibodies, and autoimmune ganglionopathy , 2009, Autonomic Neuroscience.

[8]  R. Freeman,et al.  Antibody titers predict clinical features of autoimmune autonomic ganglionopathy , 2009, Autonomic Neuroscience.

[9]  J. Lindstrom,et al.  Characterization of ganglionic acetylcholine receptor autoantibodies , 2008, Journal of Neuroimmunology.

[10]  R. Freeman,et al.  Combined immunomodulatory therapy in autoimmune autonomic ganglionopathy. , 2008, Archives of neurology.

[11]  W. Shen,et al.  Postural orthostatic tachycardia syndrome: the Mayo clinic experience. , 2007, Mayo Clinic proceedings.

[12]  P. Tonali,et al.  Chronic autoimmune autonomic neuropathy responsive to immunosuppressive therapy , 2007, Neurology.

[13]  A. Lipp,et al.  Plasma exchange for primary autoimmune autonomic failure. , 2005, The New England journal of medicine.

[14]  R. Freeman,et al.  l-DOPS therapy for refractory orthostatic hypotension in autoimmune autonomic neuropathy , 2005, Neurology.

[15]  V. Lennon,et al.  Autoantibody Profiles and Neurological Correlations of Thymoma , 2004, Clinical Cancer Research.

[16]  J. Szurszewski,et al.  Passive Transfer of Autoimmune Autonomic Neuropathy to Mice , 2004, The Journal of Neuroscience.

[17]  P. Low,et al.  Experimental autoimmune autonomic neuropathy. , 2003, Journal of neurophysiology.

[18]  P. Sandroni,et al.  The spectrum of autoimmune autonomic neuropathies , 2003, Annals of neurology.

[19]  J. Szurszewski,et al.  Immunization with neuronal nicotinic acetylcholine receptor induces neurological autoimmune disease. , 2003, The Journal of clinical investigation.

[20]  Fan Wang,et al.  Functional Properties of Human Nicotinic Achrs Expressed by Imr-32 Neuroblastoma Cells Resemble Those of α3β4 Achrs Expressed in Permanently Transfected Hek Cells , 2001, The Journal of general physiology.

[21]  G. Farrugia,et al.  Autoantibodies to ganglionic acetylcholine receptors in autoimmune autonomic neuropathies. , 2000, The New England journal of medicine.

[22]  A. Beaudet,et al.  Megacystis, mydriasis, and ion channel defect in mice lacking the alpha3 neuronal nicotinic acetylcholine receptor. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[23]  S. Boehm,et al.  Somatic and prejunctional nicotinic receptors in cultured rat sympathetic neurones show different agonist profiles , 1999, The Journal of physiology.

[24]  J. Bufler,et al.  Purified IgG from seropositive and seronegative patients with myasthenia gravis reversibly blocks currents through nicotinic acetylcholine receptor channels , 1998, Annals of neurology.

[25]  C. Lucchinetti,et al.  Paraneoplastic and oncologic profiles of patients seropositive for type 1 antineuronal nuclear autoantibodies , 1998, Neurology.

[26]  J. Koelman,et al.  Unusual recovery from acute panautonomic neuropathy after immunoglobulin therapy. , 1997, Mayo Clinic proceedings.

[27]  M. Camilleri,et al.  Idiopathic autonomic neuropathy , 1994, Neurology.

[28]  E. Sher,et al.  Antibody induced internalization of acetylcholine nicotinic receptor: kinetics, mechanism and selectivity. , 1985, European journal of cell biology.

[29]  J. Michelson,et al.  Myasthenic antibodies cross-link acetylcholine receptors to accelerate degradation. , 1978, The New England journal of medicine.

[30]  R. Young,et al.  Pure pan-dysautonomia with recovery. Description and discussion of diagnostic criteria. , 1975, Brain : a journal of neurology.